News | April 06, 2011

SMT Announces Financing for Embolic Protection Device for TAVI Procedures

April 6, 2011 – Development of a novel embolic protection device designed for use during transcatheter aortic valve implantation (TAVI) procedures received $10.5 million in funding. SMT Research and Development (SMT) of Israel announced the significant investment by OrbiMed Advisors.

The goal of the collaboration is improved safety through reduction in the number of strokes and post-procedure brain lesions.

Post-procedure brain lesion formation has been reported in the literature to occur in 68 percent to 91 percent of TAVI procedures on MRI, and the incidence of symptomatic stroke following TAVI has been reported to be between 3 percent and 10 percent in most series. Anticipating this problem, SMT has spent five years developing and refining a deflection device specifically designed to reduce the chance of stroke and embolic events during TAVI and other structural heart procedures.

"TAVI is truly one of the most exciting areas of medicine today, allowing patients suffering from life-threatening aortic valve stenosis to receive new, functional heart valves via minimally invasive techniques, thereby replacing traumatic open heart surgery," said Dov Shimon, M.D., cardiac surgeon and founder of SMT. "Current TAVI devices are working well, but despite efforts to refine the technique, we continue to see post-procedure complications associated with cerebral embolism resulting in stroke and other ischemic events."

The company initiated a pilot clinical study in early 2010. Pieter Stella, M.D., of the University Medical Center in Utrecht, The Netherlands, has performed the first-in-man cases using the SMT device.

"TAVI is an exciting new procedure for patients and cardiologists," said Stella. "However, as with any new procedure, new risks arise. It is clear from the published studies in TAVI that embolic events do occur and need to be minimized. The SMT device is the first embolic protection device that I have seen that offers coverage of all three primary vessels feeding the brain. I have been pleased with our early results, and believe that the SMT deflector will help to ensure the continued market expansion for safe, effective TAVI procedures."

"We like the fact that the SMT device was designed from the perspective of a highly-experienced surgeon who understands the anatomy of the aortic arch and the variability of arteries that branch off to deliver blood to the brain and central nervous system," said OrbiMed principal and new SMT board member, David Bonita, M.D. "To our knowledge, this is the only device in development designed to protect the entire neurovascular system by covering all three major arteries feeding the brain – the innominate, the left common carotid and the left subclavian. SMT is also the only system designed for placement via one of two femoral artery access ports typically used in TAVI – unlike other approaches which require a third puncture located in the arm."

The SMT deflector device is an investigational device and is not available for commercial use in the United States, Europe or other markets of the world.

For more information:

Related Content

Sentinel Cerebral Protection System Reaches 50-Center Adoption Milestone in U.S.
News | Embolic Protection Devices | February 19, 2018
Claret Medical announced that since U.S. Food and Drug Administration (FDA) clearance in June 2017, its Sentinel...
The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices | October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the
Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System
News | Embolic Protection Devices | October 23, 2017
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by Lights
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices | September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices | September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices | August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices | April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices | March 22, 2017
March 22, 2017 — Two U.S.
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices | September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices | September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
Overlay Init